4
MARKET OVERVIEW
This section summarizes market dynamics, key shifts, and high-impact trends shaping demand outlook.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN DIABETES CARE INDUSTRY
5.2.4
TRENDS IN INSULIN DELIVERY SYSTEMS INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022–2025
5.6.2
AVERAGE SELLING PRICE TREND, BY COUNTRY, 2022–2025
5.7.1
IMPORT SCENARIO (HS CODE 9027)
5.7.2
EXPORT SCENARIO (HS CODE 9027)
5.8
KEY CONFERENCES AND EVENTS,
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.12
IMPACT OF 2025 US TARIFF – LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES
5.12.5
IMPACT ON END USERS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.6
IMPACT OF AI ON LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES ADOPTED BY COMPANIES IN LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET
6.6.3
CASE STUDIES RELATED TO AI IMPLEMENTATION IN LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET
6.6.4
INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED BLOOD GLUCOSE MONITORS IN LATIN AMERICA
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
EPIDEMIOLOGY OF DIABETES, BY KEY COUNTRY
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4
UNMET NEEDS OF VARIOUS END-USE INDUSTRIES
9
LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET DATA, BY PRODUCT (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
9.2
SELF-MONITORING BLOOD GLUCOSE SYSTEMS
9.2.3
LANCETS & LANCING DEVICES
9.3
CONTINUOUS GLUCOSE MONITORING SYSTEMS
9.3.3
TRANSMITTERS & RECEIVERS
9.4
PROFESSIONAL POINT OF CARE DEVICES
9.5
NON-INVASIVE PRODUCTS
10
LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET DATA, BY TEST SITE (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
10.4
ALTERNATE SITES (SUCH AS ABDOMEN, THIGH, CALF, PALM, ETC.)
11
LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET DATA, BY APPLICATION (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
11.3
HEALTH AND WELLNESS MONITORING
11.4
OTHER APPLICATIONS (REMOTE MONITORING, GESTATIONAL DIABETES)
12
LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET DATA, BY END USER (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
12.5
OTHER END USERS (AMBULATORY CARE CENTERS, REHABILITATION CENTERS, AND OLD AGE HOMES)
13
LATIN AMERICA BLOOD GLUCOSE MONITOR MARKET DATA, BY COUNTRY (MARKET SIZE & FORECAST TO 2030 – IN VALUE, USD MILLION & VOLUME UNITS)
13.4
REST OF LATIN AMERICA
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
14.3
REVENUE ANALYSIS, 2020–2024
14.4
MARKET SHARE ANALYSIS,
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.5.5.1
COMPANY FOOTPRINT
14.5.5.2
COUNTRY FOOTPRINT
14.5.5.3
PRODUCT FOOTPRINT
14.5.5.4
TEST SITE FOOTPRINT
14.5.5.5
APPLICATION FOOTPRINT
14.5.5.6
END USER FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.7
COMPETITIVE SCENARIO
15.7.4
OTHER DEVELOPMENTS
15.8
BRAND/PRODUCT COMPARISON
15.8.1
ABBOTT LABORATORIES (FREESTYLE)
15.8.2
DEXCOM, INC. (G6 & G7 CGM)
15.8.3
MEDTRONIC (GUARDIAN)
15.8.4
F. HOFFMANN-LA ROCHE AG (ACCU-CHEK)
15.9
COMPANY VALUATION AND FINANCIAL METRICS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, INDUSTRY-SPECIFIC DEVELOPMENTS FOR 2022-2025)
16.1.1
ABBOTT LABORATORIES
16.1.4
F. HOFFMANN-LA ROCHE LTD
16.1.8
ASCENSIA DIABETES CARE HOLDINGS AG
16.1.11
SD BIOSENSOR, INC
16.1.13
TERUMO CORPORATION
16.1.14
LIFESCAN IP HOLDINGS, LLC
16.1.15
MEDICAL TECHNOLOGY AND DEVICES S.P.A.
17.1.1.1
LIST OF KEY SECONDARY SOURCES
17.1.1.2
KEY DATA FROM SECONDARY SOURCES
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.3
MARKET SIZE CALCULATION FOR BASE YEAR
17.3
MARKET FORECAST APPROACH
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Latin America Blood Glucose Monitor Market